Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.62 |
| ▸ | DRD4 | P21917 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233241 | 0.90 | LMNA (0.82) | LMNASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL4151775 | 0.85 | GRM2 (0.81) | LMNASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL4305298 | 0.82 | GRM2 (0.58) | LMNASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL12728853 | 0.81 | KDM4E (0.73) | LMNASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL20371574 | 0.80 | KDM4E (0.68) | LMNASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL11741784 | 0.78 | RAB9A (0.67) | LMNAMAPTKDM4EGRM2POLB | |
| SCHEMBL6844252 | 0.76 | MAPT (0.49) | LMNASMN1; SMN2MAPTHTTMEN1 | |
| SCHEMBL4138559 | 0.75 | GRM2 (1.00) | LMNASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL4147946 | 0.74 | GRM2 (0.83) | LMNASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL4152030 | 0.74 | GRM2 (0.75) | LMNASMN1; SMN2MAPTHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | LMNA 3907/4885SMN1; SMN2 3250/4885MAPT 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.